| Bioactivity | Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody containing two different Fab arms, targeting extracellular domains of HER2 and HER3[1]. |
| Invitro | Zenocutuzumab（0.001-1000 nM；96 小时）抑制肺癌和乳腺癌细胞系的细胞生长[1]。Zenocutuzumab（0.1-1000 nM；24 小时）抑制 HER3 和 AKT 磷酸化，在肺癌和乳腺癌细胞系中诱导细胞凋亡和细胞周期停滞的标志物[1]。 Cell Viability Assay[1] Cell Line: |
| In Vivo | Zenocutuzumab（2.5-25 mg/kg；腹腔注射；每周一次；持续 28 天）导致生长显着减少，包括肿瘤消退[1]。 Animal Model: |
| Name | Zenocutuzumab |
| CAS | 1969309-56-5 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Alison M Schram, et al. Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements. Cancer Discov. 2022 May 2;12(5):1233-1247. |